Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NIAR=NARI=IMLB now IMLB -- Ignore unavailable to you. Want to Upgrade?

To: peter michaelson who wrote (10)	11/2/2000 10:09:56 AM
From: peter michaelson	Read Replies (1) \| Respond to of 25

Immulabs' Board Approves Four-for-One Stock Split SCANDIA, MN -- Oct. 25, 2000 -- Immulabs Corporation's (OTCBB:IMLB) Board of Directors today declared a four-for-one split of the Company's common stock. All shareholders of record as of October 31st, 2000 shall participate in the split. The stock split affects all issued capital stock and will not change shareholders' pre-existing proportionate ownership. Shareholders are advised to contact their broker if they desire further details. About Immulabs: Immulabs Corporation is a development-stage biotechnology company with the goal of commercializing discoveries involving the immune system and host resistance to infections and other diseases in humans and higher animals. Immulab's vision is to acquire BioTech / BioMed technologies, nearing market readiness, that provide unique and valuable benefits to the immune system. If successful, the Company intends to then develop an infrastructure for global commercialization of those technologies. Immulabs is set to announce an acquisition of project(s) involving such technologies. Immulabs Corp. is managed by Cyclone Financing Group Inc, (CFGi) specializing in the incubation of public companies. CFGi will guide Immulabs through the initial stages of its development until senior industry management has been retained. Nasdaq Index firms in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services include Amgen Inc. (NASDAQ:AMGN), Biogen, Inc. (NASDAQ:BGEN), Genzyme Corporation (NASDAQ:GENZ), Human Genome Sciences, Inc.( NASDAQ:HGSI), Immunex Corporation (NASDAQ:IMNX), Medimmune Inc. (NASDAQ:MEDI). CONTACT: Immulabs Corporation Mark Sommer, 888/763-6547 or 604-646-5516 www.immulabs.com